Effects of long-term use of macrolides in patients with non-cystic fibrosis bronchiectasis: a meta-analysis of randomized controlled trials

[1] McShane PJ(2013)Non-cystic fibrosis bronchiectasis Am J Respir Crit Care Med 188 647-56

[2] Naureckas ET(2010)British Thoracic Society guideline for non-CF bronchiectasis Thorax 65 i1-58

[3] Tino G(2012)Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007 Chest 142 432-9

[4] Strek ME(2013)Bronchiectasis-associated hospitalizations in Germany, 2005–2011: a population-based study of disease burden and trends PLoS One 8 e71109-15

[5] Pasteur MC(1986)Inflammation: a two-edged sword–the model of bronchiectasis Eur J Respir Dis Suppl 147 6-75

[6] Bilton D(2013)New advances in the therapy of non-cystic fibrosis bronchiectasis Rev Port Pneumol 19 266-38

[7] Hill AT(2013)Antibacterial and immunomodulatory properties of azithromycin treatment implications for periodontitis Inflammopharmacology 21 321-84

[8] Seitz AE(2013)A novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-kappaB inhibition J Pharmacol Exp Ther 345 76-615

[9] Olivier KN(2010)Mechanisms of action and clinical application of macrolides as immunomodulatory medications Clin Microbiol Rev 23 590-9

[10] Adjemian J(1999)Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection Eur Respir J 13 1371-8

[1] McShane PJ(2013)Non-cystic fibrosis bronchiectasis Am J Respir Crit Care Med 188 647-56

[2] Naureckas ET(2010)British Thoracic Society guideline for non-CF bronchiectasis Thorax 65 i1-58

[3] Tino G(2012)Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007 Chest 142 432-9

[4] Strek ME(2013)Bronchiectasis-associated hospitalizations in Germany, 2005–2011: a population-based study of disease burden and trends PLoS One 8 e71109-15

[5] Pasteur MC(1986)Inflammation: a two-edged sword–the model of bronchiectasis Eur J Respir Dis Suppl 147 6-75

[6] Bilton D(2013)New advances in the therapy of non-cystic fibrosis bronchiectasis Rev Port Pneumol 19 266-38

[7] Hill AT(2013)Antibacterial and immunomodulatory properties of azithromycin treatment implications for periodontitis Inflammopharmacology 21 321-84

[8] Seitz AE(2013)A novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-kappaB inhibition J Pharmacol Exp Ther 345 76-615

[9] Olivier KN(2010)Mechanisms of action and clinical application of macrolides as immunomodulatory medications Clin Microbiol Rev 23 590-9

[10] Adjemian J(1999)Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection Eur Respir J 13 1371-8